阿里健康(00241.HK)與和瑞基因達成戰略合作
阿里健康(00241.HK)與和瑞基因簽署戰略合作協議,將共同打造以「互聯網平台+腫瘤早篩技術+醫療保障」為核心的腫瘤早篩普惠醫療創新服務模式。
雙方將在醫療產品服務、疾病預防、健康管理服務、科普教育、大數據醫療等多個維度展開合作。阿里健康副總裁陳波表示,基於阿里健康全場景的醫療服務能力,及和瑞基因高特異性的基因組檢測技術和大樣本臨床研究,此次合作將在疾病保障服務上全面探索,運用科技創新圍繞更多疾病設計健康管理新模式。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
![](/hk/assets/image/code.84ab0b.png)
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.